{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:33:50Z","timestamp":1783377230455,"version":"3.54.6"},"reference-count":3,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:p>This meta-analysis of individual patient data from 6 clinical trials confirms the efficacy of existing therapies in patients with progressive multiple sclerosis showing disease activity and assesses the role of lesion reduction as a mediator of treatment effect.<\/jats:p>","DOI":"10.1001\/jamaneurol.2025.2565","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T15:00:23Z","timestamp":1753714823000},"page":"1075","source":"Crossref","is-referenced-by-count":6,"title":["Modulation of Treatment Effect on Disability by Disease Activity in Progressive Multiple Sclerosis"],"prefix":"10.1001","volume":"82","author":[{"given":"Noemi","family":"Montobbio","sequence":"first","affiliation":[{"name":"Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bovis","sequence":"additional","affiliation":[{"name":"Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas L.","family":"Arnold","sequence":"additional","affiliation":[{"name":"Research, NeuroRx, Montr\u00e9al, Quebec, Canada"},{"name":"Montr\u00e9al Neurological Institute, McGill University, Montr\u00e9al, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Sormani","sequence":"additional","affiliation":[{"name":"Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy"},{"name":"IRCCS Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"nld250009r1","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1177\/13524585221094944","article-title":"Is the effect of drugs in progressive MS only due to an effect on inflammation? a subgroup meta-analysis of randomised trials.","volume":"28","author":"Capanna","year":"2022","journal-title":"Mult Scler"},{"issue":"4","key":"nld250009r2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"key":"nld250009r3","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2017035","article-title":"Applied mediation analyses: a review and tutorial.","volume":"39","author":"Lange","year":"2017","journal-title":"Epidemiol Health"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2836765\/jamaneurology_montobbio_2025_ld_250009_1758903894.43775.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T15:02:07Z","timestamp":1760367727000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2836765"}},"subtitle":["An Individual Patient Data Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":3,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2025.2565","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}